{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:00:35Z","timestamp":1793037635519,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Immunovant, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00415-026-13662-y","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:47:39Z","timestamp":1777110459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Burden of Disease in Myasthenia Gravis: A Targeted Literature Review"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7424-4719","authenticated-orcid":false,"given":"Mamatha","family":"Pasnoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley-Ann","family":"Miller-Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriy","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Copley-Merriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Muppidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"13662_CR1","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B (2021) Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med 10:2235. https:\/\/doi.org\/10.3390\/jcm10112235","journal-title":"J Clin Med"},{"key":"13662_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A et al (2019) Myasthenia gravis. Nat Rev Dis Primers 5:30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"13662_CR3","doi-asserted-by":"publisher","first-page":"e066445","DOI":"10.1136\/bmjopen-2022-066445","volume":"13","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Philips G, Paci S et al (2023) Patient-reported burden of myasthenia gravis: baseline results of the international prospective, observational, longitudinal real-world digital study MyRealWorld-MG. BMJ Open 13:e066445. https:\/\/doi.org\/10.1136\/bmjopen-2022-066445","journal-title":"BMJ Open"},{"key":"13662_CR4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.nmd.2021.05.007","volume":"31","author":"LK Andersen","year":"2021","unstructured":"Andersen LK, Aadahl M, Vissing J (2021) Fatigue, physical activity and associated factors in 779 patients with myasthenia gravis. Neuromuscul Disord 31:716\u2013725. https:\/\/doi.org\/10.1016\/j.nmd.2021.05.007","journal-title":"Neuromuscul Disord"},{"key":"13662_CR5","doi-asserted-by":"publisher","first-page":"e00538","DOI":"10.1002\/brb3.538","volume":"6","author":"S Hoffmann","year":"2016","unstructured":"Hoffmann S, Ramm J, Grittner U et al (2016) Fatigue in myasthenia gravis: risk factors and impact on quality of life. Brain Behav 6:e00538. https:\/\/doi.org\/10.1002\/brb3.538","journal-title":"Brain Behav"},{"key":"13662_CR6","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R et al (2022) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol 269:3050\u20133063. https:\/\/doi.org\/10.1007\/s00415-021-10891-1","journal-title":"J Neurol"},{"key":"13662_CR7","doi-asserted-by":"publisher","first-page":"175628642211503","DOI":"10.1177\/17562864221150327","volume":"16","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J et al (2023) Healthcare resource use in myasthenia gravis: a US health claims analysis. Ther Adv Neurol Disord 16:17562864221150328. https:\/\/doi.org\/10.1177\/17562864221150327","journal-title":"Ther Adv Neurol Disord"},{"key":"13662_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.irn.2025.04.028","volume":"182","author":"NE Gilhus","year":"2025","unstructured":"Gilhus NE, Breiner A (2025) Epidemiology of myasthenia gravis. Int Rev Neurobiol 182:161\u2013196. https:\/\/doi.org\/10.1016\/bs.irn.2025.04.028","journal-title":"Int Rev Neurobiol"},{"key":"13662_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000539577","volume":"59","author":"F Sciancalepore","year":"2024","unstructured":"Sciancalepore F, Sciancalepore F, Lombardi N et al (2024) Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: a systematic review. Neuroepidemiology 59:579\u2013592. https:\/\/doi.org\/10.1159\/000539577","journal-title":"Neuroepidemiology"},{"key":"13662_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/jnnp-2023-333097","volume":"95","author":"J Vissing","year":"2024","unstructured":"Vissing J, Atula S, Savolainen M et al (2024) Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study. J Neurol Neurosurg Psychiatry 95:919\u2013926. https:\/\/doi.org\/10.1136\/jnnp-2023-333097","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13662_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","volume":"19","author":"F Vanoli","year":"2022","unstructured":"Vanoli F, Mantegazza R (2022) Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics 19:897\u2013910. https:\/\/doi.org\/10.1007\/s13311-022-01181-3","journal-title":"Neurotherapeutics"},{"key":"13662_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s42399-025-02095-9","volume":"7","author":"T Asghar","year":"2025","unstructured":"Asghar T, Akbar SMA, Hassan SMS et al (2025) Temporal trends in mortality from myasthenia gravis and respiratory failure in the United States (1999\u20132020): insights from CDC WONDER. SN Compr Clin Med 7:311. https:\/\/doi.org\/10.1007\/s42399-025-02095-9","journal-title":"SN Compr Clin Med"},{"key":"13662_CR13","unstructured":"Gray C, Greene N, DeCourcy J, et al (2023) Disease burden, treatment landscape, and health-related quality of life outcomes in myasthenia gravis: results from the Adelphi Real-world Disease Specific Programme in the United States and Europe. Presented at: The Professional Society for Health Economics and Outcomes Research (ISPOR) 2023 Conference; May 7\u201310, Boston, MA, USA."},{"key":"13662_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajo.2019.04.017","volume":"205","author":"TM Hendricks","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ (2019) Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol 205:99\u2013105. https:\/\/doi.org\/10.1016\/j.ajo.2019.04.017","journal-title":"Am J Ophthalmol"},{"key":"13662_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ajo.2019.09.019","volume":"209","author":"S Apinyawasisuk","year":"2020","unstructured":"Apinyawasisuk S, Chongpison Y, Thitisaksakul C, Jariyakosol S (2020) Factors affecting generalization of ocular myasthenia gravis in patients with positive acetylcholine receptor antibody. Am J Ophthalmol 209:10\u201317. https:\/\/doi.org\/10.1016\/j.ajo.2019.09.019","journal-title":"Am J Ophthalmol"},{"key":"13662_CR16","doi-asserted-by":"publisher","first-page":"e70081","DOI":"10.1002\/hsr2.70081","volume":"7","author":"M Yung","year":"2024","unstructured":"Yung M, Narayanaswami P, Pesa J et al (2024) Patient and care partner perspectives and preferences related to myasthenia gravis treatment: a qualitative study. Heal Sci Rep 7:e70081. https:\/\/doi.org\/10.1002\/hsr2.70081","journal-title":"Heal Sci Rep"},{"key":"13662_CR17","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/j.lanwpc.2020.100063","volume":"5","author":"J Chen","year":"2020","unstructured":"Chen J, Tian D-C, Zhang C et al (2020) Incidence, mortality, and economic burden of myasthenia gravis in China: a nationwide population-based study. Lancet Reg Heal: West Pac 5:100063. https:\/\/doi.org\/10.1016\/j.lanwpc.2020.100063","journal-title":"Lancet Reg Heal: West Pac"},{"key":"13662_CR18","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1212\/con.0000000000000800","volume":"25","author":"E Ciafaloni","year":"2019","unstructured":"Ciafaloni E (2019) Myasthenia gravis and congenital myasthenic syndromes. Continuum 25:1767\u20131784. https:\/\/doi.org\/10.1212\/con.0000000000000800","journal-title":"Continuum"},{"key":"13662_CR19","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s40120-025-00845-4","volume":"14","author":"T Webb","year":"2025","unstructured":"Webb T, Kasahara-Kiritani M, Herr K et al (2025) Clinical status, treatment, and disease burden of generalised myasthenia gravis in the Asia-Pacific. Neurol Ther 14:2625\u20132645. https:\/\/doi.org\/10.1007\/s40120-025-00845-4","journal-title":"Neurol Ther"},{"key":"13662_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000209104","author":"L-A Miller-Wilson","year":"2025","unstructured":"Miller-Wilson L-A, Lal L, Conyers J et al (2025) Clinical outcomes and events in a United States generalized myasthenia gravis population: analysis of real-world data (P12-11.032). Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000209104","journal-title":"Neurology"},{"key":"13662_CR21","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.nmd.2020.06.010","volume":"30","author":"AM Ruiter","year":"2020","unstructured":"Ruiter AM, Verschuuren JJGM, Tannemaat MR (2020) Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromuscul Disord 30:631\u2013639. https:\/\/doi.org\/10.1016\/j.nmd.2020.06.010","journal-title":"Neuromuscul Disord"},{"key":"13662_CR22","doi-asserted-by":"publisher","first-page":"5665","DOI":"10.1007\/s00415-024-12490-2","volume":"271","author":"M Funke","year":"2024","unstructured":"Funke M, Eveslage M, Zsch\u00fcntzsch J et al (2024) Fatigue and associated factors in myasthenia gravis: a nationwide registry study. J Neurol 271:5665\u20135670. https:\/\/doi.org\/10.1007\/s00415-024-12490-2","journal-title":"J Neurol"},{"issue":"Suppl 1","key":"13662_CR23","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/ene.15461","volume":"29","author":"M Kleman","year":"2022","unstructured":"Kleman M, Myren K, Tursunova S et al (2022) Frequency of diagnosed comorbid conditions amongst myasthenia gravis patients: analysis of real-world data. Eur J Neurol 29(Suppl 1):611. https:\/\/doi.org\/10.1111\/ene.15461","journal-title":"Eur J Neurol"},{"key":"13662_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036. https:\/\/doi.org\/10.1016\/s1474-4422(15)00145-3","journal-title":"Lancet Neurol"},{"key":"13662_CR25","doi-asserted-by":"publisher","first-page":"1625457","DOI":"10.3389\/fneur.2025.1625457","volume":"16","author":"H Teranishi","year":"2025","unstructured":"Teranishi H, Tsuda K, Harada D et al (2025) Treatment patterns and impact of glucocorticoids on health outcomes in generalized myasthenia gravis: a retrospective observational study based on the Medical Data Vision database in Japan. Front Neurol 16:1625457. https:\/\/doi.org\/10.3389\/fneur.2025.1625457","journal-title":"Front Neurol"},{"key":"13662_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","volume":"22","author":"L Harris","year":"2022","unstructured":"Harris L, Graham S, MacLachlan S et al (2022) A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurol 22:172. https:\/\/doi.org\/10.1186\/s12883-022-02692-4","journal-title":"BMC Neurol"},{"key":"13662_CR27","doi-asserted-by":"publisher","first-page":"123322","DOI":"10.1016\/j.jns.2024.123322","volume":"468","author":"CZ Qi","year":"2025","unstructured":"Qi CZ, Lin Y, Li Y et al (2025) Characteristics and healthcare utilization of patients with myasthenia gravis exacerbation. J Neurol Sci 468:123322. https:\/\/doi.org\/10.1016\/j.jns.2024.123322","journal-title":"J Neurol Sci"},{"key":"13662_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/mus.25965","volume":"57","author":"C Barraud","year":"2018","unstructured":"Barraud C, Desguerre I, Barnerias C et al (2018) Clinical features and evolution of juvenile myasthenia gravis in a French cohort. Muscle Nerve 57:603\u2013609. https:\/\/doi.org\/10.1002\/mus.25965","journal-title":"Muscle Nerve"},{"key":"13662_CR29","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40120-022-00383-3","volume":"11","author":"M Mahic","year":"2022","unstructured":"Mahic M, Bozorg AM, DeCourcy JJ et al (2022) Physician-reported perspectives on Myasthenia Gravis in the United States: a real-world survey. Neurol Ther 11:1535\u20131551. https:\/\/doi.org\/10.1007\/s40120-022-00383-3","journal-title":"Neurol Ther"},{"key":"13662_CR30","doi-asserted-by":"publisher","first-page":"e1382","DOI":"10.1212\/wnl.0000000000012604","volume":"97","author":"M Petersson","year":"2021","unstructured":"Petersson M, Feresiadou A, Jons D et al (2021) Patient-reported symptom severity in a Nationwide Myasthenia Gravis Cohort: cross-sectional analysis of the Swedish GEMG Study. Neurology 97:e1382\u2013e1391. https:\/\/doi.org\/10.1212\/wnl.0000000000012604","journal-title":"Neurology"},{"key":"13662_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12883-024-03553-y","volume":"24","author":"J McCallion","year":"2024","unstructured":"McCallion J, Borsi A, Noel W et al (2024) Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa. BMC Neurol 24:61. https:\/\/doi.org\/10.1186\/s12883-024-03553-y","journal-title":"BMC Neurol"},{"key":"13662_CR32","unstructured":"Pesa J, Choudhry Z, DeCourcy J, et al (2023) Correlation Between Myasthenia Gravis Disease Severity and Impairment of Activities of Daily Living among Real-World Patients in the United States and Five European Countries. Presented at: The Professional Society for Health Economics and Outcomes Research (ISPOR) 2023 Conference; May 7\u201310, Boston, MA, USA."},{"key":"13662_CR33","doi-asserted-by":"publisher","first-page":"120268","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G et al (2022) The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci 437:120268. https:\/\/doi.org\/10.1016\/j.jns.2022.120268","journal-title":"J Neurol Sci"},{"key":"13662_CR34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12955-020-01549-z","volume":"18","author":"D Dong","year":"2020","unstructured":"Dong D, Chong MK, Wu Y et al (2020) Gender differences in quality of life among patients with myasthenia gravis in China. Health Qual Life Outcomes 18:296. https:\/\/doi.org\/10.1186\/s12955-020-01549-z","journal-title":"Health Qual Life Outcomes"},{"key":"13662_CR35","doi-asserted-by":"publisher","first-page":"175628642513447","DOI":"10.1177\/17562864251344742","volume":"18","author":"F Beeching","year":"2025","unstructured":"Beeching F, Lecchi A, Riccitelli GC (2025) Female gender and quality of life outcomes in myasthenia gravis: a systematic review and meta-analysis. Ther Adv Neurol Disord 18:17562864251344742. https:\/\/doi.org\/10.1177\/17562864251344742","journal-title":"Ther Adv Neurol Disord"},{"key":"13662_CR36","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1007\/s12325-023-02604-z","volume":"40","author":"S Dewilde","year":"2023","unstructured":"Dewilde S, Phillips G, Paci S et al (2023) People diagnosed with myasthenia gravis have lower health-related quality of life and need more medical and caregiver help in comparison to the general population: analysis of two observational studies. Adv Ther 40:4377\u20134394. https:\/\/doi.org\/10.1007\/s12325-023-02604-z","journal-title":"Adv Ther"},{"key":"13662_CR37","doi-asserted-by":"publisher","first-page":"19275","DOI":"10.1038\/s41598-022-22078-3","volume":"12","author":"D Marbin","year":"2022","unstructured":"Marbin D, Piper SK, Lehnerer S et al (2022) Mental health in myasthenia gravis patients and its impact on caregiver burden. Sci Rep 12:19275. https:\/\/doi.org\/10.1038\/s41598-022-22078-3","journal-title":"Sci Rep"},{"key":"13662_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jocn.2023.11.024","volume":"119","author":"D-D Meng","year":"2024","unstructured":"Meng D-D, Ruan Z, Tang Y-L et al (2024) Factors associated with the disease family burden of caregivers of myasthenia gravis patients in northwestern China: a cross-sectional study. J Clin Neurosci 119:70\u201375. https:\/\/doi.org\/10.1016\/j.jocn.2023.11.024","journal-title":"J Clin Neurosci"},{"key":"13662_CR39","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T et al (2020) Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics 38:715\u2013728. https:\/\/doi.org\/10.1007\/s40273-020-00912-8","journal-title":"Pharmacoeconomics"},{"key":"13662_CR40","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40258-024-00897-x","volume":"22","author":"M Zhdanava","year":"2024","unstructured":"Zhdanava M, Pesa J, Boonmak P et al (2024) Predictors of high healthcare cost among patients with generalized myasthenia gravis: a combined machine learning and regression approach from a US payer perspective. Appl Health Econ Health Policy 22:735\u2013747. https:\/\/doi.org\/10.1007\/s40258-024-00897-x","journal-title":"Appl Health Econ Health Policy"},{"key":"13662_CR41","doi-asserted-by":"publisher","first-page":"472","DOI":"10.18553\/jmcp.2025.31.5.472","volume":"31","author":"SA Choi","year":"2025","unstructured":"Choi SA, Touchette DR, Kim K (2025) Health care costs and resource utilization among patients with myasthenia gravis in the United States. J Manag Care Sp\u00e9c Pharm 31:472\u2013481. https:\/\/doi.org\/10.18553\/jmcp.2025.31.5.472","journal-title":"J Manag Care Sp\u00e9c Pharm"},{"key":"13662_CR42","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.1038\/s41598-025-91372-7","volume":"15","author":"S Lehnerer","year":"2025","unstructured":"Lehnerer S, Herdick M, Mevius A et al (2025) The economic burden of myasthenia gravis from the patient\u00b4s perspective and reflected in German claims data. Sci Rep 15:6687. https:\/\/doi.org\/10.1038\/s41598-025-91372-7","journal-title":"Sci Rep"},{"key":"13662_CR43","doi-asserted-by":"publisher","first-page":"e16367","DOI":"10.1016\/j.heliyon.2023.e16367","volume":"9","author":"G Antonini","year":"2023","unstructured":"Antonini G, Habetswallner F, Inghilleri M et al (2023) Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon 9:e16367. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367","journal-title":"Heliyon"},{"key":"13662_CR44","doi-asserted-by":"publisher","first-page":"e16511","DOI":"10.1111\/ene.16511","volume":"31","author":"F Piehl","year":"2024","unstructured":"Piehl F, Vissing J, Meht\u00e4l\u00e4 J et al (2024) Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: a population\u2010based registry study. Eur J Neurol 31:e16511. https:\/\/doi.org\/10.1111\/ene.16511","journal-title":"Eur J Neurol"},{"key":"13662_CR45","doi-asserted-by":"publisher","first-page":"e230108","DOI":"10.57264\/cer-2023-0108","volume":"13","author":"J Pisc","year":"2024","unstructured":"Pisc J, Ting A, Skornicki M et al (2024) Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data. J Comp Eff Res 13:e230108. https:\/\/doi.org\/10.57264\/cer-2023-0108","journal-title":"J Comp Eff Res"},{"key":"13662_CR46","doi-asserted-by":"publisher","first-page":"S451","DOI":"10.1016\/j.jval.2022.09.2242","volume":"25","author":"S Jacob","year":"2022","unstructured":"Jacob S, Betts A, Hosnijeh F, Binns J (2022) RWD17 a retrospective observational study on the healthcare resource use of patients with myasthenia gravis in secondary care in England using hospital episodes statistics. Value Health 25:S451. https:\/\/doi.org\/10.1016\/j.jval.2022.09.2242","journal-title":"Value Health"},{"key":"13662_CR47","doi-asserted-by":"publisher","first-page":"S494","DOI":"10.1016\/j.jval.2022.04.1085","volume":"25","author":"C Qi","year":"2022","unstructured":"Qi C, Hughes T, Li Y et al (2022) HSD85 real-world usage patterns and costs of IVIG treatment in adults with generalized myasthenia gravis in the United States. Value Health 25:S494\u2013S495. https:\/\/doi.org\/10.1016\/j.jval.2022.04.1085","journal-title":"Value Health"},{"key":"13662_CR48","unstructured":"Alexion Pharmaceuticals, Inc. European Commission Grants New Indication for Soliris\u00ae (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) [Press Release]. 2017. Accessed November 22, 2024. https:\/\/media.alexion.com\/news-releases\/news-release-details\/european-commission-grants-new-indication-solirisr-eculizumab"},{"key":"13662_CR49","unstructured":"SOLIRIS\u00ae (eculizumab). Full Prescribing Information. Alexion Pharmaceuticals; 2024."},{"key":"13662_CR50","unstructured":"ULTOMIRIS\u00ae (ravulizumab-cwvz). Full Prescribing Information. Alexion Pharmaceuticals; 2024."},{"key":"13662_CR51","unstructured":"AstraZeneca (2022) Ultomiris approved in the US for adults with generalised myasthenia gravis. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/ultomiris-approved-in-the-us-for-adults-with-generalised-myasthenia-gravis.html#"},{"key":"13662_CR52","unstructured":"UCB (2023) UCB announces U.S. FDA approval of RYSTIGGO[\u00ae] (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis. https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/ucb-announces-us-fda-approval-of-rystiggor-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis#:~:text=Brussels%20(Belgium)%2007%3A00,the%20treatment%20of%20generalized%20myasthenia"},{"key":"13662_CR53","unstructured":"UCB (2023) UCB announces U.S. FDA approval of ZILBRYSQ[\u00ae] (zilucoplan) for the treatment of adults with generalized myasthenia gravis. https:\/\/www.ucb.com\/newsroom\/press-releases\/article\/ucb-announces-us-fda-approval-of-zilbrysqr-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis"},{"key":"13662_CR54","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40801-024-00457-8","volume":"11","author":"RJ Nowak","year":"2024","unstructured":"Nowak RJ, Habib AA, Klink AJ et al (2024) US clinical practice experience with eculizumab in myasthenia gravis: acute clinical events and healthcare resource utilization. Drugs-Real World Outcomes 11:593\u2013601. https:\/\/doi.org\/10.1007\/s40801-024-00457-8","journal-title":"Drugs-Real World Outcomes"},{"key":"13662_CR55","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","volume":"54","author":"E Guastafierro","year":"2020","unstructured":"Guastafierro E, Tramacere I, Toppo C et al (2020) Employment in Myasthenia Gravis: a systematic literature review and meta-analysis. Neuroepidemiology 54:304\u2013312. https:\/\/doi.org\/10.1159\/000506310","journal-title":"Neuroepidemiology"},{"key":"13662_CR56","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","volume":"60","author":"L Harris","year":"2019","unstructured":"Harris L, Aban IB, Xin H, Cutter G (2019) Employment in refractory myasthenia gravis: a myasthenia gravis foundation of america registry analysis. Muscle Nerve 60:700\u2013706. https:\/\/doi.org\/10.1002\/mus.26694","journal-title":"Muscle Nerve"},{"key":"13662_CR57","doi-asserted-by":"publisher","first-page":"1538789","DOI":"10.3389\/fpubh.2025.1538789","volume":"13","author":"S Dewilde","year":"2025","unstructured":"Dewilde S, Qi CZ, Ruyck FD et al (2025) A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity. Front Public Heal 13:1538789. https:\/\/doi.org\/10.3389\/fpubh.2025.1538789","journal-title":"Front Public Heal"},{"key":"13662_CR58","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","volume":"40","author":"A Evoli","year":"2019","unstructured":"Evoli A, Antonini G, Antozzi C et al (2019) Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol Sci 40:1111\u20131124. https:\/\/doi.org\/10.1007\/s10072-019-03746-1","journal-title":"Neurol Sci"},{"key":"13662_CR59","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/wnl.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M et al (2016) International consensus guidance for management of myasthenia gravis executive summary. Neurology 87:419\u2013425. https:\/\/doi.org\/10.1212\/wnl.0000000000002790","journal-title":"Neurology"},{"key":"13662_CR60","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s13760-024-02552-7","volume":"124","author":"JLD Bleecker","year":"2024","unstructured":"Bleecker JLD, Remiche G, Alonso-Jim\u00e9nez A et al (2024) Recommendations for the management of myasthenia gravis in Belgium. Acta Neurol Belg 124:1371\u20131383. https:\/\/doi.org\/10.1007\/s13760-024-02552-7","journal-title":"Acta Neurol Belg"},{"key":"13662_CR61","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/pn-2025-004655","volume":"25","author":"S Jacob","year":"2025","unstructured":"Jacob S, Farrugia ME, Hewamadduma C et al (2025) Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update). Pract Neurol 25:422\u2013437. https:\/\/doi.org\/10.1136\/pn-2025-004655","journal-title":"Pract Neurol"},{"key":"13662_CR62","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/wnl.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96:114\u2013122. https:\/\/doi.org\/10.1212\/wnl.0000000000011124","journal-title":"Neurology"},{"key":"13662_CR63","doi-asserted-by":"publisher","first-page":"e16229","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK et al (2024) Generalized myasthenia gravis with acetylcholine receptor antibodies: a guidance for treatment. Eur J Neurol 31:e16229. https:\/\/doi.org\/10.1111\/ene.16229","journal-title":"Eur J Neurol"},{"key":"13662_CR64","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A et al (2023) Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord 16:17562864231213240. https:\/\/doi.org\/10.1177\/17562864231213240","journal-title":"Ther Adv Neurol Disord"},{"key":"13662_CR65","doi-asserted-by":"publisher","first-page":"1576405","DOI":"10.3389\/fneur.2025.1576405","volume":"16","author":"L Jackson","year":"2025","unstructured":"Jackson L, Brethenoux C, DeLuca A et al (2025) AI-based thematic exploration to understand patients with myasthenia gravis by serological subtype. Front Neurol 16:1576405. https:\/\/doi.org\/10.3389\/fneur.2025.1576405","journal-title":"Front Neurol"},{"key":"13662_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.nrl.2025.501912","author":"E Cort\u00e9s-Vicente","year":"2025","unstructured":"Cort\u00e9s-Vicente E, Casasnovas C, Juntas R et al (2025) Myasthenia gravis in Spain: A survey of specialized neurologists to uncover unmet needs. Neurologia. https:\/\/doi.org\/10.1016\/j.nrl.2025.501912","journal-title":"Neurologia"},{"key":"13662_CR67","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/03007995.2025.2516147","volume":"41","author":"J Pesa","year":"2025","unstructured":"Pesa J, Choudhry Z, de Courcy J et al (2025) Patient and physician concordance in treatment satisfaction and symptom severity among myasthenia gravis patients in the United States and five European countries. Curr Med Res Opin 41:841\u2013854. https:\/\/doi.org\/10.1080\/03007995.2025.2516147","journal-title":"Curr Med Res Opin"},{"key":"13662_CR68","unstructured":"Bohn J, Jacobsen M, Conover M, et al (2023) Real world treatment pathways among adult patients with myasthenia gravis. The Professional Society for Health Economics and Outcomes Research (ISPOR) 2023 Conference; May 7\u201310, Boston, MA, USA."},{"key":"13662_CR69","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R et al (2022) Utilization of MG\u2010ADL in myasthenia gravis clinical research and care. Muscle Nerve 65:630\u2013639. https:\/\/doi.org\/10.1002\/mus.27476","journal-title":"Muscle Nerve"},{"key":"13662_CR70","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1001\/jamaneurol.2019.5125","volume":"77","author":"JF Howard","year":"2020","unstructured":"Howard JF, Nowak RJ, Wolfe GI et al (2020) Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol 77:582. https:\/\/doi.org\/10.1001\/jamaneurol.2019.5125","journal-title":"JAMA Neurol"},{"key":"13662_CR71","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","volume":"267","author":"J Vissing","year":"2020","unstructured":"Vissing J, Jacob S, Fujita KP et al (2020) \u2018Minimal symptom expression\u2019 in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol 267:1991\u20132001. https:\/\/doi.org\/10.1007\/s00415-020-09770-y","journal-title":"J Neurol"},{"key":"13662_CR72","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/acn3.70167","volume":"12","author":"N Chahin","year":"2025","unstructured":"Chahin N, Sahagian G, Feinberg MH et al (2025) Durability of response to B\u2010cell maturation antigen-directed mRNA cell therapy in myasthenia gravis. Ann Clin Transl Neurol 12:2358\u20132366. https:\/\/doi.org\/10.1002\/acn3.70167","journal-title":"Ann Clin Transl Neurol"},{"key":"13662_CR73","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi C, Vu T, Ramchandren S et al (2025) Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol 24:105\u2013116. https:\/\/doi.org\/10.1016\/s1474-4422(24)00498-8","journal-title":"Lancet Neurol"},{"key":"13662_CR74","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/acn3.70051","volume":"12","author":"AA Habib","year":"2025","unstructured":"Habib AA, Claeys KG, Bril V et al (2025) ADAPT NXT: fixed cycles or every\u2010other\u2010week IV efgartigimod in generalized myasthenia gravis. Ann Clin Transl Neurol 12:1162\u20131170. https:\/\/doi.org\/10.1002\/acn3.70051","journal-title":"Ann Clin Transl Neurol"},{"key":"13662_CR75","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s1474-4422(23)00080-7","volume":"22","author":"JF Howard","year":"2023","unstructured":"Howard JF, Bresch S, Genge A et al (2023) Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol 22:395\u2013406. https:\/\/doi.org\/10.1016\/s1474-4422(23)00080-7","journal-title":"Lancet Neurol"},{"key":"13662_CR76","doi-asserted-by":"publisher","first-page":"175628642412431","DOI":"10.1177\/17562864241243186","volume":"17","author":"JF Howard","year":"2024","unstructured":"Howard JF, Bresch S, Farmakidis C et al (2024) Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study. Ther Adv Neurol Disord 17:17562864241243186. https:\/\/doi.org\/10.1177\/17562864241243186","journal-title":"Ther Adv Neurol Disord"},{"key":"13662_CR77","doi-asserted-by":"publisher","first-page":"123628","DOI":"10.1016\/j.jns.2025.123628","volume":"476","author":"JF Howard","year":"2025","unstructured":"Howard JF, Dodig D, Zeinali L et al (2025) First analysis of the Myasthenia Gravis SPOTLIGHT Registry: outcomes with eculizumab and ravulizumab. J Neurol Sci 476:123628. https:\/\/doi.org\/10.1016\/j.jns.2025.123628","journal-title":"J Neurol Sci"},{"key":"13662_CR78","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000205792","author":"S Muppidi","year":"2024","unstructured":"Muppidi S, Howard J, Murai H et al (2024) Achievement of minimal symptom expression and effect on disease-specific measures in acetylcholine receptor antibody-positive participants with generalized myasthenia gravis treated with efgartigimod in ADAPT\/ADAPT+ (P10-11.009). Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000205792","journal-title":"Neurology"},{"key":"13662_CR79","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/s1474-4422(24)00514-3","volume":"24","author":"AA Habib","year":"2025","unstructured":"Habib AA, Zhao C, Aban I et al (2025) Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 24:117\u2013127. https:\/\/doi.org\/10.1016\/s1474-4422(24)00514-3","journal-title":"Lancet Neurol"},{"key":"13662_CR80","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000210678","author":"T Vu","year":"2025","unstructured":"Vu T, Li Y, Howard JF et al (2025) Long-term safety and efficacy of subcutaneous efgartigimod PH20 in adult participants with generalized myasthenia gravis: interim results of the ADAPT-SC+ study (P1-11.005). Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000210678","journal-title":"Neurology"},{"key":"13662_CR81","doi-asserted-by":"publisher","first-page":"e70158","DOI":"10.1111\/ene.70158","volume":"32","author":"TH Vu","year":"2025","unstructured":"Vu TH, Mantegazza R, Annane D et al (2025) Long\u2010term efficacy and safety of ravulizumab in adults with anti\u2010acetylcholine receptor antibody\u2010positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open\u2010label extension. Eur J Neurol 32:e70158. https:\/\/doi.org\/10.1111\/ene.70158","journal-title":"Eur J Neurol"},{"key":"13662_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0044","author":"C Yan","year":"2024","unstructured":"Yan C, Yue Y, Guan Y et al (2024) Batoclimab vs placebo for generalized myasthenia gravis. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0044","journal-title":"JAMA Neurol"},{"key":"13662_CR83","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/01455613211025937","volume":"100","author":"RT Sataloff","year":"2021","unstructured":"Sataloff RT, Bush ML, Chandra R et al (2021) Systematic and other reviews: criteria and complexities. Ear Nose Throat J 100:403\u2013406. https:\/\/doi.org\/10.1177\/01455613211025937","journal-title":"Ear Nose Throat J"},{"key":"13662_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-26837-4_8","author":"DA Cook","year":"2019","unstructured":"Cook DA (2019) Systematic and nonsystematic reviews: choosing an approach. Healthcare Simulat Res. https:\/\/doi.org\/10.1007\/978-3-030-26837-4_8","journal-title":"Healthcare Simulat Res"},{"key":"13662_CR85","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1016\/j.jval.2023.03.1848","volume":"26","author":"J Pesa","year":"2023","unstructured":"Pesa J, Choudhry Z, Courcy JD et al (2023) PCR70 patient and physician concordance in treatment satisfaction and symptom severity among male and female myasthenia gravis patients in the United States and five European countries. Value Health 26:S324. https:\/\/doi.org\/10.1016\/j.jval.2023.03.1848","journal-title":"Value Health"},{"key":"13662_CR86","doi-asserted-by":"publisher","first-page":"e048198","DOI":"10.1136\/bmjopen-2020-048198","volume":"11","author":"S Berrih-Aknin","year":"2021","unstructured":"Berrih-Aknin S, Claeys KG, Law N et al (2021) Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG). BMJ Open 11:e048198. https:\/\/doi.org\/10.1136\/bmjopen-2020-048198","journal-title":"BMJ Open"},{"key":"13662_CR87","doi-asserted-by":"publisher","first-page":"S351","DOI":"10.1016\/j.jval.2023.03.2391","volume":"26","author":"J Pesa","year":"2023","unstructured":"Pesa J, Choudhry Z, Courcy JD et al (2023) PCR212 correlation between myasthenia gravis disease severity and impairment of daily living activities of real-world patients in the United States and five European countries. Value Health 26:S351. https:\/\/doi.org\/10.1016\/j.jval.2023.03.2391","journal-title":"Value Health"},{"key":"13662_CR88","doi-asserted-by":"publisher","first-page":"S406","DOI":"10.1016\/j.jval.2022.09.2017","volume":"25","author":"S Dewilde","year":"2022","unstructured":"Dewilde S, Paci S, Iannazzo S et al (2022) PCR82 association between myasthenia gravis-activities of daily living (MG-ADL) and Eq-5D-5L utility values: the additional effect of efgartigimod on utilities. Value Heal 25:S406. https:\/\/doi.org\/10.1016\/j.jval.2022.09.2017","journal-title":"Value Heal"},{"key":"13662_CR89","doi-asserted-by":"publisher","unstructured":"Mina-Osorio P, Arackal J, Wang J, Schwinn J, Venker B (2023). Incidence and prevalence of myasthenia gravis: Analysis of a US commercial insurance claims database. Muscle Nerve 68:476\u2013686. Abstract 288. https:\/\/doi.org\/10.1002\/mus.27968","DOI":"10.1002\/mus.27968"},{"key":"13662_CR90","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000202945","author":"E Rodrigues","year":"2023","unstructured":"Rodrigues E, Umeh E, Uday A et al (2023) Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis (S19.007). Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000202945","journal-title":"Neurology"},{"key":"13662_CR91","doi-asserted-by":"publisher","first-page":"S255","DOI":"10.1016\/j.jval.2023.03.1407","volume":"26","author":"M Tierney","year":"2023","unstructured":"Tierney M, Chen J, Taylor SS, Cibelli E (2023) HSD100 exploring the path to diagnosis for patients with myasthenia gravis using real-world data. Value Heal 26:S255\u2013S256. https:\/\/doi.org\/10.1016\/j.jval.2023.03.1407","journal-title":"Value Heal"},{"key":"13662_CR92","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/cnd.0000000000000257","volume":"20","author":"AN Boscoe","year":"2019","unstructured":"Boscoe AN, Xin H, L\u2019Italien GJ et al (2019) Impact of refractory myasthenia gravis on health-related quality of life. J Clin Neuromuscul Dis 20:173\u2013181. https:\/\/doi.org\/10.1097\/cnd.0000000000000257","journal-title":"J Clin Neuromuscul Dis"},{"key":"13662_CR93","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mus.27659","volume":"66","author":"I Lee","year":"2022","unstructured":"Lee I, Leach JM, Aban I et al (2022) One\u2010year follow\u2010up of disease burden and medication changes in patients with myasthenia gravis: from the MG patient registry. Muscle Nerve 66:411\u2013420. https:\/\/doi.org\/10.1002\/mus.27659","journal-title":"Muscle Nerve"},{"key":"13662_CR94","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijcard.2019.09.054","volume":"299","author":"R Desai","year":"2020","unstructured":"Desai R, Abbas SA, Fong HK et al (2020) Burden and impact of takotsubo syndrome in myasthenic crisis: a national inpatient perspective on the under-recognized but potentially fatal association. Int J Cardiol 299:63\u201366. https:\/\/doi.org\/10.1016\/j.ijcard.2019.09.054","journal-title":"Int J Cardiol"},{"key":"13662_CR95","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1016\/j.jval.2023.03.920","volume":"26","author":"Y Kohen","year":"2023","unstructured":"Kohen Y, Buser H, Nair A et al (2023) EPH38 burden of psychiatric health in elderly myasthenia gravis patients: a nationwide Medicare perspective. Value Health 26:S171. https:\/\/doi.org\/10.1016\/j.jval.2023.03.920","journal-title":"Value Health"},{"key":"13662_CR96","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","volume":"58","author":"NM Engel\u2010Nitz","year":"2018","unstructured":"Engel\u2010Nitz NM, Boscoe A, Wolbeck R et al (2018) Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve 58:99\u2013105. https:\/\/doi.org\/10.1002\/mus.26114","journal-title":"Muscle Nerve"},{"issue":"Suppl 1","key":"13662_CR97","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/ene.15461","volume":"29","author":"M Kleman","year":"2022","unstructured":"Kleman M, Myren K, Tursunova S et al (2022) Impact of generalised myasthenia gravis on activities of daily living and employment for patients and caregivers. Eur J Neurol 29(Suppl 1):612. https:\/\/doi.org\/10.1111\/ene.15461","journal-title":"Eur J Neurol"},{"key":"13662_CR98","doi-asserted-by":"publisher","first-page":"120531","DOI":"10.1016\/j.jns.2022.120531","volume":"445","author":"A Ting","year":"2023","unstructured":"Ting A, Story T, Lecomte C et al (2023) A real-world analysis of factors associated with high healthcare resource utilization and costs in patients with myasthenia gravis receiving second-line treatment. J Neurol Sci 445:120531. https:\/\/doi.org\/10.1016\/j.jns.2022.120531","journal-title":"J Neurol Sci"},{"key":"13662_CR99","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.18553\/jmcp.2022.28.10-a.s1","volume":"28","author":"A Estrin","year":"2022","unstructured":"Estrin A, Ting A, Shah R, Lee E (2022) Treatment patterns and healthcare resourceutilization among patients with myastheniagravis starting acetylcholinesterase inhibitors, non-steroidal immunosuppressant therapy, or biologics: a retrospective cohort study in the United States. J Manag Care Spec Pharm 28:S78. https:\/\/doi.org\/10.18553\/jmcp.2022.28.10-a.s1","journal-title":"J Manag Care Spec Pharm"},{"key":"13662_CR100","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3988\/jcn.2019.15.3.376","volume":"15","author":"H Xin","year":"2019","unstructured":"Xin H, Harris LA, Aban IB, Cutter G (2019) Examining the impact of refractory myasthenia gravis on healthcare resource utilization in the United States: analysis of a Myasthenia Gravis Foundation of America patient registry sample. J Clin Neurol 15:376\u2013385. https:\/\/doi.org\/10.3988\/jcn.2019.15.3.376","journal-title":"J Clin Neurol"},{"key":"13662_CR101","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski HJ, Cutter G et al (2010) Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 68:797\u2013805. https:\/\/doi.org\/10.1002\/ana.22139","journal-title":"Ann Neurol"},{"key":"13662_CR102","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000529583","volume":"57","author":"H Wartmann","year":"2023","unstructured":"Wartmann H, Hoffmann S, Ruck T et al (2023) Incidence, prevalence, hospitalization rates, and treatment patterns in myasthenia gravis: a 10-year real-world data analysis of German claims data. Neuroepidemiology 57:121\u2013128. https:\/\/doi.org\/10.1159\/000529583","journal-title":"Neuroepidemiology"},{"key":"13662_CR103","doi-asserted-by":"publisher","first-page":"e01819","DOI":"10.1002\/brb3.1819","volume":"10","author":"E Westerberg","year":"2020","unstructured":"Westerberg E, Punga AR (2020) Epidemiology of myasthenia gravis in Sweden 2006\u20132016. Brain Behav 10:e01819. https:\/\/doi.org\/10.1002\/brb3.1819","journal-title":"Brain Behav"},{"key":"13662_CR104","unstructured":"Cai Q, Zhang Q, B\u00f6rsum J, et al Direct and indirect costs among employed patients with myasthenia gravis in Sweden. Presented at: The Professional Society for Health Economics and Outcomes Research (ISPOR) 2023 Conference; May 7\u201310, 2023; Boston, MA, USA."},{"key":"13662_CR105","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1159\/000512973","volume":"55","author":"E Sobieszczuk","year":"2021","unstructured":"Sobieszczuk E, Napi\u00f3rkowski \u0141, Szczudlik P, Kostera-Pruszczyk A (2021) Myasthenia gravis in Poland: national healthcare database epidemiological study. Neuroepidemiology 55:62\u201369. https:\/\/doi.org\/10.1159\/000512973","journal-title":"Neuroepidemiology"},{"key":"13662_CR106","doi-asserted-by":"publisher","first-page":"880045","DOI":"10.3389\/fneur.2022.880045","volume":"13","author":"P Jiang","year":"2022","unstructured":"Jiang P, Li J, Li H-Y et al (2022) Minimal manifestation status indicates a stable state in myasthenia gravis: a quantitative study. Front Neurol 13:880045. https:\/\/doi.org\/10.3389\/fneur.2022.880045","journal-title":"Front Neurol"},{"key":"13662_CR107","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/cen3.12736","volume":"14","author":"H Yoshikawa","year":"2023","unstructured":"Yoshikawa H (2023) Epidemiological study of myasthenia gravis in Japan. Clin Exp Neuroimmunol 14:13\u201318. https:\/\/doi.org\/10.1111\/cen3.12736","journal-title":"Clin Exp Neuroimmunol"},{"key":"13662_CR108","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/cen3.12495","volume":"10","author":"H Murai","year":"2019","unstructured":"Murai H, Hasebe M, Murata T, Utsugisawa K (2019) Clinical burden and healthcare resource utilization associated with myasthenia gravis: assessments from a Japanese claims database. Clin Exp Neuroimmunol 10:61\u201368. https:\/\/doi.org\/10.1111\/cen3.12495","journal-title":"Clin Exp Neuroimmunol"},{"key":"13662_CR109","doi-asserted-by":"publisher","first-page":"e0274161","DOI":"10.1371\/journal.pone.0274161","volume":"17","author":"H Yoshikawa","year":"2022","unstructured":"Yoshikawa H, Adachi Y, Nakamura Y et al (2022) Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018. PLoS ONE 17:e0274161. https:\/\/doi.org\/10.1371\/journal.pone.0274161","journal-title":"PLoS ONE"},{"key":"13662_CR110","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/ane.13596","volume":"145","author":"J Park","year":"2022","unstructured":"Park J, Eah KY, Park J (2022) Epidemiological profile of myasthenia gravis in South Korea using the national health insurance database. Acta Neurol Scand 145:633\u2013640. https:\/\/doi.org\/10.1111\/ane.13596","journal-title":"Acta Neurol Scand"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13662-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13662-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13662-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:44:02Z","timestamp":1779446642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13662-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["13662"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13662-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mamatha Pasnoor has served on advisory board meetings and as a consultant for Immunovant, Amgen, CSL Behring, Grifols, argenx, Annexon, Janssen, Johnson and Johnson, Catalyst, UCB. Kati Copley-Merriman and Jessica Costello are employees of RTI Health Solutions. Allison Foss has served as a representative on the Leadership Council for argenx and for the Rare Disease Connect in Neurology (RDCN) learning program led by UCB, and as a participant for the Regeneron Patient Council; she has also received compensation for speaking engagements with Amgen, Cartesian Therapeutics and Immunovant, Inc. Lesley-Ann Miller-Wilson and Yuriy Edwards are employees of Immunovant, Inc. Srikanth Muppidi has served on advisory board meetings for Alexion, AstraZeneca Rare Disease, argenx, Horizon Therapeutics, and Ra Pharmaceuticals (now UCB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"288"}}